Case Studies
 Cytomyx
- Biotech drug discovery company quoted on AIM market of the London Stock Exchange
- Board sought to divest company to realize cash return in light of depressed market capitalisation
- Sage identified Serologicals (now part of Millipore)
- Negotiated final terms, which were double the initial offer, for the sale of Cytomyx ion channel discovery business
- Price was cash at 3 times the market cap and five times revenue, leaving significant residual value in the business
|
 Return to all case studies
|